Preclinical and clinical studies have suggested potential synergies of combining poly (ADP-ribose) polymerase (PARP) inhibitors and novel hormonal therapies (NHT) for patients with metastatic castration-resistant prostate cancer (mCRPC). We systematically searched PubMed. ClinicalTrials. gov and ASCO-GU annual meeting abstracts up to March 2023 to identify potential phase III trials r... https://www.hindigyanvishv.com/